OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $24.00

OrthoPediatrics (NASDAQ:KIDS) had its price target increased by BTIG Research from $23.00 to $24.00 in a report published on Friday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

Several other analysts have also issued reports on the company. Canaccord Genuity Group initiated coverage on OrthoPediatrics in a report on Wednesday, December 10th. They set a “buy” rating and a $24.00 target price on the stock. Needham & Company LLC boosted their price target on OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Thursday, January 22nd. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, Wall Street Zen lowered shares of OrthoPediatrics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.44.

OrthoPediatrics Stock Performance

Shares of KIDS stock opened at $19.17 on Friday. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $26.40. The company’s fifty day simple moving average is $17.64 and its 200-day simple moving average is $18.13. The firm has a market cap of $480.78 million, a PE ratio of -11.34 and a beta of 1.07. The company has a quick ratio of 3.52, a current ratio of 7.40 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.11. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.68%. The firm had revenue of $61.61 million for the quarter, compared to analyst estimates of $61.27 million. Equities research analysts expect that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

Several large investors have recently modified their holdings of the stock. Invesco Ltd. boosted its holdings in shares of OrthoPediatrics by 14.5% during the 4th quarter. Invesco Ltd. now owns 39,002 shares of the company’s stock worth $693,000 after buying an additional 4,925 shares during the period. XTX Topco Ltd acquired a new stake in OrthoPediatrics during the fourth quarter worth approximately $188,000. Tudor Investment Corp ET AL boosted its holdings in shares of OrthoPediatrics by 59.3% during the fourth quarter. Tudor Investment Corp ET AL now owns 112,996 shares of the company’s stock worth $2,007,000 after acquiring an additional 42,061 shares during the period. Millennium Management LLC boosted its holdings in shares of OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after acquiring an additional 452,840 shares during the period. Finally, Engineers Gate Manager LP acquired a new position in shares of OrthoPediatrics in the fourth quarter valued at approximately $226,000. 69.05% of the stock is owned by institutional investors.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Q4 beat — OrthoPediatrics reported EPS of ($0.26) vs. consensus ($0.37) and revenue of $61.61M vs. $61.27M, a combination that surprised the market to the upside. Earnings Release
• Positive Sentiment: Needham raised its price target to $30 and reiterated a Buy — the new target implies material upside versus the current share level and likely supported buying interest. Benzinga
• Positive Sentiment: BTIG also raised its target to $24 and kept a Buy rating, adding further analyst support to the stock move. Benzinga
• Positive Sentiment: Company reiterated 2026 revenue guidance of $262M–$266M and described an accelerating “product innovation super‑cycle,” which management frames as a multi‑year growth driver. Seeking Alpha
• Neutral Sentiment: Investor access: OrthoPediatrics announced participation in upcoming investor conferences, which should help management communicate the growth story but is not material on its own. GlobeNewswire
• Neutral Sentiment: Analyst/media coverage and detailed call notes/transcript are circulating (earnings transcript and coverage from Yahoo, Zacks, Seeking Alpha), which helps investors parse the quarter. Yahoo Finance
• Negative Sentiment: Profitability remains a concern — OrthoPediatrics is still loss‑making (negative net margin ~20% and negative ROE), and consensus expects negative full‑year EPS, which limits valuation multiple expansion until sustained profit improvement. Zacks

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.